Fibrosis-Inflammation Lab

⌘K

Fibrosis-Inflammation Lab

Accelerating fibrosis and inflammation research through validated preclinical models and expert insights.

Research

Models
Drugs
Insights
Resources
Pathways

Company

About
Contact Us
Privacy Policy

© 2026 Fibrosis-Inflammation Lab. All rights reserved.

/

/

Lanifibranor (Lanifibranor) | Accelerate Your Fibrosis Research

Home/Drugs/Lanifibranor

Lanifibranor

Lanifibranor

Phase 3

Sponsor: Inventiva

Indication: MASH

Mechanism of Action

Pan-PPAR Agonist

Target: PPAR-alphaTarget: PPAR-deltaTarget: PPAR-gamma

Clinical Information

Approval Year

Clinical Trials (ClinicalTrials.gov)

COMPLETEDNCT05232071

Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus

Phase:PHASE2Org:Inventiva Pharma

COMPLETEDNCT02503644

Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis

Phase:PHASE2Org:Inventiva Pharma

COMPLETEDNCT03866369

Multiple Ascending Dose Phase I Study in Order to Define Lanifibranor (IVA337) Supra-thjerapeutic Dose

Phase:PHASE1Org:Inventiva Pharma

COMPLETEDNCT06126562

A Pharmacokinetic Study of Lanifibranor in Healthy Adult Chinese Subjects

Phase:PHASE1Org:Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

COMPLETEDNCT03459079

Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease

Phase:PHASE2Org:University of Florida

View all trials on ClinicalTrials.gov

Relevant Publications (PubMed)

GLP-1R-GIPR-PPARα/γ/δ quintuple agonism corrects obesity and diabetes in mice.

Liskiewicz D, Novikoff A, Khalil A et al.

Nature2026 Apr 29

Efficacy of tirzepatide, lanifibranor, and resmetirom in metabolic dysfunction-associated steatotic liver disease: a meta-analysis of high-quality randomized controlled trials.

Zhao S, Tian F, Yu L et al.

Intern Emerg Med2026 Mar 31

An Extravascular Synergistic Cocktail Therapeutic Strategy Based on Lanifibranor Loaded Self-Healing Bioelastomer for Abdominal Aortic Aneurysms.

Hu J, Dai W, Xu Z et al.

Adv Mater2026 Mar 29

Close multilevel links between metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus.

Holleboom AG, Francque SM, Cusi K et al.

Metabol Open2025 Dec

Pathogenesis and Treatment of Non-alcoholic Steatohepatitis and Its Fibrosis: A Systematic Review.

Ahmed T, Farooq S, Naveed MA et al.

Cureus2025 Aug

View more on PubMed

Validated Models

This drug has been validated in the following preclinical models: